Scholarlink

Background <p>Soluble programmed death ligand 1 (sPD-L1) reflects immune–inflammatory activity and may serve as a circulating biomarker of hepatocarcinogenesis. Whether baseline sPD-L1 predicts de novo hepatocellular carcinoma (HCC) in patients without existing HCC remains unclear.</p> Aims <p>To determine whether serum sPD-L1 predicts future HCC across distinct virological backgrounds of chronic hepatitis C.</p> Methods <p>Two temporally and clinically distinct cohorts from Nagasaki Medical Center were analyzed. The SVR cohort included 430 patients who achieved sustained virological response after direct-acting antiviral therapy (2013–2017). A historical pre-DAA cohort (n = 692), consisting of viremic patients who underwent liver biopsy between 1992 and 2003, served as an independent temporal validation cohort. Baseline sPD-L1 was measured in all patients. Cox proportional hazards models, stratified analyses, landmark analysis, and time-dependent models were applied to assess the association between sPD-L1 and HCC.</p> Results <p>High baseline sPD-L1 independently predicted increased HCC risk in both cohorts (SVR: HR 2.61, 95% CI 1.02–6.71; historical: HR 1.90, 95% CI 1.32–2.74). In the SVR cohort, sPD-L1 stratified HCC risk within high-risk groups defined by aMAP, M2BPGi, or FIB-4. In the historical cohort, sPD-L1 stratified HCC risk even within low-risk strata defined by aMAP and FIB-4. Notably, patients with low sPD-L1 rarely developed HCC despite advanced fibrosis.</p> Conclusions <p>Baseline sPD-L1 predicts de novo HCC development independently of virological status and fibrosis-based indices. Concordant findings across two distinct temporal cohorts support sPD-L1 as a robust preclinical biomarker of hepatocarcinogenesis. Incorporating sPD-L1 into surveillance algorithms may enhance individualized HCC risk stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum soluble PD-L1 predicts hepatocellular carcinoma development across distinct virological cohorts of chronic hepatitis C

  • 期刊论文

  • 发表日期：

    2026年4月7日

查看全文
  • Kazumi Yamasaki,
  • Masashi Mizokami,
  • Megumi Goto,
  • Shinya Nagaoka,
  • Akira Saeki,
  • Yasuhide Motoyoshi,
  • Tomoyuki Suehiro,
  • Yuki Kugiyama,
  • Atsumasa Komori,
  • Jun Ohashi,
  • Hiroshi Yatsuhashi

摘要

Background

Soluble programmed death ligand 1 (sPD-L1) reflects immune–inflammatory activity and may serve as a circulating biomarker of hepatocarcinogenesis. Whether baseline sPD-L1 predicts de novo hepatocellular carcinoma (HCC) in patients without existing HCC remains unclear.

Aims

To determine whether serum sPD-L1 predicts future HCC across distinct virological backgrounds of chronic hepatitis C.

Methods

Two temporally and clinically distinct cohorts from Nagasaki Medical Center were analyzed. The SVR cohort included 430 patients who achieved sustained virological response after direct-acting antiviral therapy (2013–2017). A historical pre-DAA cohort (n = 692), consisting of viremic patients who underwent liver biopsy between 1992 and 2003, served as an independent temporal validation cohort. Baseline sPD-L1 was measured in all patients. Cox proportional hazards models, stratified analyses, landmark analysis, and time-dependent models were applied to assess the association between sPD-L1 and HCC.

Results

High baseline sPD-L1 independently predicted increased HCC risk in both cohorts (SVR: HR 2.61, 95% CI 1.02–6.71; historical: HR 1.90, 95% CI 1.32–2.74). In the SVR cohort, sPD-L1 stratified HCC risk within high-risk groups defined by aMAP, M2BPGi, or FIB-4. In the historical cohort, sPD-L1 stratified HCC risk even within low-risk strata defined by aMAP and FIB-4. Notably, patients with low sPD-L1 rarely developed HCC despite advanced fibrosis.

Conclusions

Baseline sPD-L1 predicts de novo HCC development independently of virological status and fibrosis-based indices. Concordant findings across two distinct temporal cohorts support sPD-L1 as a robust preclinical biomarker of hepatocarcinogenesis. Incorporating sPD-L1 into surveillance algorithms may enhance individualized HCC risk stratification.